Lima Lawrence1, Venu Menon2, Sangeeta Kashyap3. 1. Cleveland Clinic, Department of Endocrinology, Diabetes and Metabolism, 9500 Euclid Ave. F20, Cleveland, OH, 44195, USA. 2. Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Ave. J1-5, Cleveland, OH, 44195, USA. 3. Cleveland Clinic, Department of Endocrinology, Diabetes and Metabolism, 9500 Euclid Ave. F20, Cleveland, OH, 44195, USA. kashyas@ccf.org.
Abstract
PURPOSE OF REVIEW: We review the cardiovascular and renal outcomes and safety of newer anti-diabetic medications in high-risk patients. We examine the outcomes of the IRIS, EMPA-REG OUTCOME, CANVAS, LEADER, SAVOR-TIMI 53, and EXAMINE trials demonstrating the cardiovascular and renal benefits of thiazolidinediones, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors. RECENT FINDINGS: Diabetes mellitus is a leading risk factor for cardiovascular disease with rising prevalence and disease burden. The microvascular and macrovascular complications of diabetes are well-recognized and include increased risk of cardiovascular disease, myocardial infarction, and stroke. Newer diabetes medications have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality benefits in high risk patients with diabetes. In addition to their glucose-lowering effects, the thiazolidinedione pioglitazone, SGLT2 inhibitors, GLP-1 agonist, and DPP-4 inhibitors have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality effects. The outcomes and safety data of newer diabetes medications from recent trials demonstrate cardiovascular and mortality effects with significant implications for clinical practice.
PURPOSE OF REVIEW: We review the cardiovascular and renal outcomes and safety of newer anti-diabetic medications in high-risk patients. We examine the outcomes of the IRIS, EMPA-REG OUTCOME, CANVAS, LEADER, SAVOR-TIMI 53, and EXAMINE trials demonstrating the cardiovascular and renal benefits of thiazolidinediones, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors. RECENT FINDINGS:Diabetes mellitus is a leading risk factor for cardiovascular disease with rising prevalence and disease burden. The microvascular and macrovascular complications of diabetes are well-recognized and include increased risk of cardiovascular disease, myocardial infarction, and stroke. Newer diabetes medications have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality benefits in high risk patients with diabetes. In addition to their glucose-lowering effects, the thiazolidinedionepioglitazone, SGLT2 inhibitors, GLP-1 agonist, and DPP-4 inhibitors have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality effects. The outcomes and safety data of newer diabetes medications from recent trials demonstrate cardiovascular and mortality effects with significant implications for clinical practice.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Emanuele Di Angelantonio; Stephen Kaptoge; David Wormser; Peter Willeit; Adam S Butterworth; Narinder Bansal; Linda M O'Keeffe; Pei Gao; Angela M Wood; Stephen Burgess; Daniel F Freitag; Lisa Pennells; Sanne A Peters; Carole L Hart; Lise Lund Håheim; Richard F Gillum; Børge G Nordestgaard; Bruce M Psaty; Bu B Yeap; Matthew W Knuiman; Paul J Nietert; Jussi Kauhanen; Jukka T Salonen; Lewis H Kuller; Leon A Simons; Yvonne T van der Schouw; Elizabeth Barrett-Connor; Randi Selmer; Carlos J Crespo; Beatriz Rodriguez; W M Monique Verschuren; Veikko Salomaa; Kurt Svärdsudd; Pim van der Harst; Cecilia Björkelund; Lars Wilhelmsen; Robert B Wallace; Hermann Brenner; Philippe Amouyel; Elizabeth L M Barr; Hiroyasu Iso; Altan Onat; Maurizio Trevisan; Ralph B D'Agostino; Cyrus Cooper; Maryam Kavousi; Lennart Welin; Ronan Roussel; Frank B Hu; Shinichi Sato; Karina W Davidson; Barbara V Howard; Maarten J G Leening; Maarten Leening; Annika Rosengren; Marcus Dörr; Dorly J H Deeg; Stefan Kiechl; Coen D A Stehouwer; Aulikki Nissinen; Simona Giampaoli; Chiara Donfrancesco; Daan Kromhout; Jackie F Price; Annette Peters; Tom W Meade; Edoardo Casiglia; Debbie A Lawlor; John Gallacher; Dorothea Nagel; Oscar H Franco; Gerd Assmann; Gilles R Dagenais; J Wouter Jukema; Johan Sundström; Mark Woodward; Eric J Brunner; Kay-Tee Khaw; Nicholas J Wareham; Eric A Whitsel; Inger Njølstad; Bo Hedblad; Sylvia Wassertheil-Smoller; Gunnar Engström; Wayne D Rosamond; Elizabeth Selvin; Naveed Sattar; Simon G Thompson; John Danesh Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: E S Mearns; W J Saulsberry; C M White; C G Kohn; S Lemieux; A Sihabout; I Salamucha; C I Coleman Journal: Diabet Med Date: 2015-07-17 Impact factor: 4.359
Authors: Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse Journal: N Engl J Med Date: 2017-08-31 Impact factor: 91.245
Authors: Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Ling Li; Sheyu Li; Ke Deng; Jiali Liu; Per Olav Vandvik; Pujing Zhao; Longhao Zhang; Jiantong Shen; Malgorzata M Bala; Zahra N Sohani; Evelyn Wong; Jason W Busse; Shanil Ebrahim; German Malaga; Lorena P Rios; Yingqiang Wang; Qunfei Chen; Gordon H Guyatt; Xin Sun Journal: BMJ Date: 2016-02-17
Authors: Lily Agrawal; Nasrin Azad; Gideon D Bahn; Peter D Reaven; Rodney A Hayward; Domenic J Reda; Nicholas V Emanuele Journal: Diabetes Care Date: 2019-09-23 Impact factor: 19.112